SEF Performs Eye Surgeries

Residing in Poughkeepsie, New York, Ram Kancherla is a managing partner of the Hudson Valley Cancer Center, where he runs the oncology private practice and oversees the financial and administrative aspects. In his free time, Ram Kancherla also supports several charities, including the Children’s Home of Poughkeepsie and the Sankara Eye Foundation.

Formed as a nonprofit to help eradicate blindness in India, the Sankara Eye Foundation has a program called Vision 2030 which aims to perform one million eye surgeries annually through 2030, thanks to its partner hospitals in India and the USA. It has at least twelve chapters in the United States, while SEF, India, acts as the service arm for the funds raised in North America.

As of 2019, SEF, India has performed more than two million free eye surgeries for those in need. Along with funds received from its generous donors, its Sankara Eye Foundation, India sector can stay in operation due to its unique self-sufficiency model in which 80 percent of its patients get their eye treatment completely free, and 20 percent of its patients pay for their treatment over time.

Chemotherapy and Breast Cancer

A graduate of Rangaraya Medical College, Ram Kancherla, MD, has served as a managing partner at the Hudson Valley Cancer Center in Poughkeepsie, New York, since 2002. In this position, Ram Kancherla, MD, is responsible for overseeing all activities within the oncology private practice, including chemotherapy.

The effectiveness of chemotherapy as a treatment for breast cancer can vary for a number of reasons, including the specific type of cancer, location of the tumor, and at which stage of the disease treatment began. That said, decades of effective chemotherapy treatments have provided insight into chemotherapy’s role in successful treatments.

Approximately 38 percent of individuals with stage 1 or 2 breast cancer undergo chemotherapy, compared to 82 and 66 percent of stage 3 and 4 cases, respectively. When breast cancer is localized, the 5-year relative survival rate in individuals who receive chemotherapy is 99 percent. If the disease has become regionalized, relative survival rates remain strong but are lower at 85 percent.

Chemotherapy, along with other forms of treatment, is far less effective once the disease has progressed to another part of the body. In these cases, survival rates can fall as low as 6 percent.

Again, it must be stressed that these rates do not solely describe the effectiveness of chemotherapy as a treatment, but rather illustrate how often chemotherapy plays a role in a successful treatment regimen. In fact, studies suggest that many breast cancer patients can avoid chemotherapy, with 5- and 9-year disease-free survival rates improving only slightly for those who receive chemotherapy.

Of course, patients must work closely with their medical teams to determine whether or not chemotherapy could play an effective role as part of their personal treatment plan.

What Is Immunotherapy?

A managing partner at Hudson Valley Cancer Center, Dr. Ram Kancherla provides advanced and compassionate care for oncology patients. Ram Kancherla, MD has performed hundreds of stem cell transplants. He is also well-versed in immunotherapy.

Immunotherapy is a type of biological therapy used as a treatment for cancer. It helps the patient’s immune system fight cancer cells in their body. The immune system comprises organs and tissues of the lymph system and white blood cells.

Additionally, the immune system is responsible for detecting and destroying abnormal cells, and it is part of its function to prevent and diminish the development of several cancers. With immunotherapy, immune cells can act better against tumors, especially because cancers have mechanisms to avoid destruction by the immune system.

Immunotherapy drugs used to treat cancer include immune checkpoint inhibitors, which block checkpoints of the immune system. These checkpoints keep immune responses from being too intense. By stopping them, inhibiting drugs allow the body to react more strongly to cancer. Patients can also receive lab-made immune system proteins, which bind to specific targets on cancer cells and help the body identify them.

What is an Autologous Stem Cell Transplant?

Managing partner at Hudson Valley Cancer Center Ram Kancherla MD runs the private oncology practice in an administrative and financial capacity. Having completed both his residency and fellowship in institutions within New York, Dr. Ram Kancherla served as the director at the Autologous Stem Cell Transplant.

Autologous stem cell transplant or autologous bone marrow transplant is a procedure in which healthy stem cells are used to replace the stem cells that have been damaged or destroyed by excess radiation and exposure to chemotherapy. Often used in the treatment of leukemia and lymphoma, an autologous stem cell transplant is preferred because it eliminates the need to worry about a patient's incompatibility with a donor's stem cells.

To perform an autologous stem cell transplant, healthcare providers will extract blood from a vein in the patient's arm. This blood sample then passes through an apheresis machine to remove the stem cells from the blood sample. After a patient's chemotherapy and radiation sessions, the stem cells are returned to replace the healthy stem cells destroyed during the cancer treatments.